1 Result: Ipsen
Momentum Surge: Elafibranor's PBC Trial Data Boosts Genfit
June 30th, 2023
Ipsen S.A. (OTCMKTS: IPSEY) and Genfit S.A. (Nasdaq: GNFT) have announced positive results from the ELATIVE Phase III trial evaluating elafibranor as a treatment for patients with primary biliary cholangitis (PBC), a rare cholestatic liver disease, w. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Member Login